Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Key Points

• Whitehawk Therapeutics has a “Moderate Buy” consensus rating: Six of eight analysts recommend buying the stock, while one rates it a hold and one a sell. The average 12-month price target is $8.20, above the reported $4.76 opening price.
• The stock recently traded higher and exceeded quarterly expectations: Shares were up 2.6%, and the company reported an adjusted loss of $0.20 per share, beating analysts’ estimate of a $0.30 loss.
• Institutional ownership is substantial: Institutional investors and hedge funds hold 52.08% of the company, with several firms recently initiating positions or increasing their stakes.

Shares of Whitehawk Therapeutics, Inc. (NASDAQ:WHWK - Get Free Report) have been given a consensus rating of "Moderate Buy" by the eight ratings firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $8.20.

A number of equities analysts have recently commented on the stock. Wall Street Zen raised shares of Whitehawk Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 8th. B. Riley Financial initiated coverage on shares of Whitehawk Therapeutics in a research note on Thursday, June 25th. They set a "buy" rating and a $10.00 price target for the company. Oppenheimer restated an "outperform" rating and issued a $7.00 price objective on shares of Whitehawk Therapeutics in a research note on Friday, May 8th. Leerink Partners initiated coverage on shares of Whitehawk Therapeutics in a report on Monday, July 13th. They issued an "outperform" rating and a $9.00 target price for the company. Finally, Weiss Ratings downgraded shares of Whitehawk Therapeutics from a "sell (d)" rating to a "sell (d-)" rating in a research note on Friday, June 5th.

Whitehawk Therapeutics Trading Up 2.6%

Shares of Whitehawk Therapeutics stock opened at $4.76 on Wednesday. The company has a fifty day simple moving average of $4.16 and a 200-day simple moving average of $3.88. The stock has a market cap of $271.36 million, a price-to-earnings ratio of -4.25 and a beta of 0.76. Whitehawk Therapeutics has a 12-month low of $1.57 and a 12-month high of $5.49.

Whitehawk Therapeutics (NASDAQ:WHWK - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.30) by $0.10. On average, analysts forecast that Whitehawk Therapeutics will post -1.1 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Quadrature Capital Ltd purchased a new stake in shares of Whitehawk Therapeutics in the fourth quarter valued at about $28,000. OMERS ADMINISTRATION Corp purchased a new position in Whitehawk Therapeutics during the first quarter worth about $40,000. Deutsche Bank AG purchased a new position in Whitehawk Therapeutics during the second quarter worth about $145,000. Bank of America Corp DE acquired a new stake in Whitehawk Therapeutics in the second quarter valued at about $159,000. Finally, Geode Capital Management LLC lifted its position in Whitehawk Therapeutics by 11.4% in the fourth quarter. Geode Capital Management LLC now owns 425,440 shares of the company's stock valued at $1,030,000 after purchasing an additional 43,686 shares during the period. Institutional investors and hedge funds own 52.08% of the company's stock.

About Whitehawk Therapeutics

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source